Physician profile
Keith W Vrbicky
NPI 1477561660
$1,406.91
in general payments reported to CMS, 2019-2025
30 companies · $81.04 in 2025
The $81.04 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $75.87 · 2021: $262 · 2022: $142 · 2023: $184 · 2024: $58.21 · 2025: $81.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $323.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $420.57 | 2019 | |
| Abbvie INC. | $410.30 | 2019-2025 | Ubrelvy, Qulipta |
| Daiichi Sankyo INC. | $132.56 | 2019-2023 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $60.98 | 2021 | |
| Minerva Surgical, INC | $56.03 | 2021 | |
| Pfizer INC. | $49.30 | 2019-2024 | |
| Allergan, INC. | $45.43 | 2020-2021 | |
| Novo Nordisk INC | $42.97 | 2022-2025 | Wegovy |
| Biogen, INC. | $39.44 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $34.30 | 2023-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $21.35 | 2023-2025 | |
| Channel Medsystems, INC. | $18.07 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.00 | 2023 | Ultomiris |
| Abbott Laboratories | $15.64 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $14.77 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.37 | 2025 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $12.83 | 2023 | Twirla |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Vrbicky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.